PROGNOSTIC VALUE OF INTRACELLULAR ADHESION MOLECULES IN HEMOLYTIC-UREMIC SYNDROME
- Authors: Moskalets O.V.1, Pankratenko T.E.1
-
Affiliations:
- Moscow Regional Research and Clinical Institute named after M. F. Vladimirskij
- Issue: Vol 22, No 2-1 (2019)
- Pages: 426-428
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/120239
- DOI: https://doi.org/10.31857/S102872210006919-5
- ID: 120239
Cite item
Full Text
Abstract
The article presents the results of a study assessing the diagnostic and prognostic significance of determining the content of soluble intercellular adhesion molecules in children with typical and atypical hemolytic-uremic syndrome.
About the authors
O. V. Moskalets
Moscow Regional Research and Clinical Institute named after M. F. Vladimirskij
Author for correspondence.
Email: 6816000@mail.ru
PhD, Leading Researcher, Research Laboratory,
Moscow
Russian FederationT. E. Pankratenko
Moscow Regional Research and Clinical Institute named after M. F. Vladimirskij
Email: fake@neicon.ru
PhD, Assistant Professor of Department of Transplantology, Nephrology and Artificial Organs, Faculty of Advanced Medical Studies,
Moscow
Russian FederationReferences
- Talarico V., Aloe M., Monzani A., Miniero R., Bona G. Hemolytic uremic syndrome in children. Minerva Pediatr.2016; 68(6), 441–445.
- Keir L. S., Marks S. D., Kim J. J. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther. 2012;6, 195–208.
- Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6, 60–66.
- Москалец О. В. Молекулы клеточной адгезии ICAM-1 и VCAM-1 при инфекционной патологии. Тихоокеанский медицинский журнал. 2018, 2, 21–25.
- Carter S., Hewitt I., Kausman J. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome. Nephrology(Cariton). 2017;22 (Suppl.1),7–10.
